Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.

ABSTRACT:

Introduction

The MET inhibitor tepotinib demonstrated durable clinical activity in patients with advanced MET exon 14 (METex14) skipping NSCLC. We report detailed analyses of adverse events of clinical interest (AECIs) in VISION, including edema, a class effect of MET inhibitors.

Patients and methods

Incidence, management, and time to first onset/resolution were analyzed for all-cause AECIs, according to composite categories (edema, hypoalbuminemia, creatinine increase, and ALT/AST increase) or individual preferred terms (pleural effusion, nausea, diarrhea, and vomiting), for patients with METex14 skipping NSCLC in the phase II VISION trial.

Results

Of 255 patients analyzed (median age: 72 years), edema, the most common AECI, was reported in 69.8% (grade 3, 9.4%; grad

SUBMITTER: Veillon R 

PROVIDER: S-EPMC10068910 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature